Blood Cancer Discoveries Grant Program
Published: 2020-07-01 |
Source: Leukemia & Lymphoma Society
Seeking to ignite the next major breakthrough to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the next exceptional scientists in the field.
The innovative Blood Cancer Discoveries Grant Program is designed to encourage researchers with deep experience in the blood cancers to conduct critical basic research in hopes of unleashing the next wave of novel approaches to treating leukemia, lymphoma, myeloma and myelodysplastic syndromes; together, these cancers are the 2nd leading cause of cancer deaths in the U.S.
"With this new initiative, LLS maintains its role as a driver of innovation, supporting early stage research to propel discoveries that might lead to the next generation of treatments and cures, and help accelerate promising therapies to patients," said Lee Greenberger, LLS's chief scientific officer.
The grants are awarded to researchers seeking to understand the biological underpinnings of various blood cancers, what causes them to develop and grow, or become resistant to treatments. Each project will be supported by an award of $750,000 over a three-year period.
The Blood Cancer Discoveries Grant Program recipients are:
Robert Bradley, Ph.D. - Fred Hutchinson Cancer Research Center
Catriona Jamieson, M.D., Ph.D. - University of California San Diego
Ronald (Ron) Levy, M.D. - Stanford University School of Medicine
Ravindra (Ravi) Majeti, M.D., Ph.D. - Stanford University School of Medicine
Markus Müschen, M.D., Ph.D. - City of Hope
Susan Schwab, Ph.D. - New York University
Margaret Shipp, M.D. - Dana-Farber Cancer Institute/Harvard Medical School
Robert Signer, Ph.D. - University of California San Diego
Daniel T. Starczynowski, Ph.D. - Cincinnati Children's Research Foundation